Travere Sale Purchase Of Stock from 2010 to 2025

TVTX Stock  USD 19.71  0.66  3.24%   
Travere Therapeutics Sale Purchase Of Stock yearly trend continues to be fairly stable with very little volatility. Sale Purchase Of Stock is likely to outpace its year average in 2025. During the period from 2010 to 2025, Travere Therapeutics Sale Purchase Of Stock regression line of annual values had r-squared of  0.66 and arithmetic mean of  7,713,838. View All Fundamentals
 
Sale Purchase Of Stock  
First Reported
2010-12-31
Previous Quarter
31.2 M
Current Value
32.7 M
Quarterly Volatility
13.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.1 M, Selling General Administrative of 277.3 M or Other Operating Expenses of 584.9 M, as well as many indicators such as Price To Sales Ratio of 6.84, Dividend Yield of 0.0 or PTB Ratio of 22.1. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Sale Purchase Of Stock Growth Pattern

Below is the plot of the Sale Purchase Of Stock of Travere Therapeutics over the last few years. It is Travere Therapeutics' Sale Purchase Of Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Sale Purchase Of Stock10 Years Trend
Slightly volatile
   Sale Purchase Of Stock   
       Timeline  

Travere Sale Purchase Of Stock Regression Statistics

Arithmetic Mean7,713,838
Geometric Mean3,168,186
Coefficient Of Variation170.54
Mean Deviation10,908,470
Median2,046,000
Standard Deviation13,155,423
Sample Variance173.1T
Range35M
R-Value0.81
Mean Square Error62.5T
R-Squared0.66
Significance0.0001
Slope2,249,954
Total Sum of Squares2596T

Travere Sale Purchase Of Stock History

202532.7 M
202431.2 M
202227.1 M
20212.1 M
2016M
2014-2.3 M

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Sale Purchase Of Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Sale Purchase Of Stock31.2 M32.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.